论文部分内容阅读
我院1975年7月—1985年12月收治130例胃癌术后化疗病人,男107例,女23例。全部病理证实,其中腺癌60例,低分化腺癌25例,印戒细胞癌5例,粘液腺癌22例,未分化癌6例,溃疡恶变2例,Ⅰ期22例,Ⅱ期3(?)例,Ⅲ期3(?)例,Ⅳ期32例。手术后3—4周开始化疗,化疗方案MFV方案49例,MF方案66例,其它方案15例。治疗结果:本组病人随访率为95.3％(124/130),五年生存率为40.8％(53/130),MFV方案五年生存率为30.6％(15/49),MF方案五年生存率为51.5％(34/66),其它方案五年生存率为26.7％(4/5).MF方案其五年生存率同MFV方案及其它方案比较有统计学意义(P<0.01)。MF方案具有给药时间短,毒副作用小,疗效好的优点。
In our hospital from July 1975 to December 1985, 130 patients with postoperative chemotherapy for gastric cancer were treated, including 107 males and 23 females. All pathological findings confirmed 60 cases of adenocarcinoma, 25 cases of poorly differentiated adenocarcinoma, 5 cases of signet ring cell carcinoma, 22 cases of mucinous adenocarcinoma, 6 cases of undifferentiated carcinoma, 2 cases of malignant ulcer, 22 cases of stage I, and 2 cases of stage II ( )) cases, stage 3 (?) cases, stage IV 32 cases. Chemotherapy was started 3-4 weeks after surgery. The MFV regimen was 49 cases, MF regimen was 66 cases, and other regimens were 15 cases. Treatment outcome: The follow-up rate of this group of patients was 95.3% (124/130), the five-year survival rate was 40.8% (53/130), the five-year survival rate of the MFV program was 30.6% (15/49), and the MF program survived for five years The rate was 51.5% (34/66). The other five-year survival rate of the other schemes was 26.7% (4/5). The five-year survival rate of the MF scheme was statistically significant compared with the MFV scheme and other schemes (P<0.01). The MF regimen has the advantages of short administration time, small toxic and side effects, and good curative effect.